Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 10, 2022 | June 15, 2022 |
| Organon & Co.OGN · Entity 4115 | Chief Information Officer | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date June 10, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,335 |
Reported balance
After 2022-06-10 transaction · row 1
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 15,556 · Balance 21,335 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2029-06-10 | Direct | 13,882 |
Reported balance
After 2022-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-10 · Grant · Acquired 13,882 · Balance 13,882 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.54 · Expires 2027-05-28 | Direct | 3,448 |
Reported balance
Holding disclosure · report date 2022-06-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,448 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.90 · Expires 2028-06-02 | Direct | 3,714 |
Reported balance
Holding disclosure · report date 2022-06-10 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,714 |
Organon & Co.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,105.292 |
Ending reported balance
After 2026-03-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-31 · Exercise / conversion · Acquired 6,555 · Balance 110,256.292 Row 2 · 2026-03-31 · Tax withholding · Disposed 2,246 · Balance 108,010.292 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Row 3 · 2026-03-31 · Exercise / conversion · Acquired 12,312 · Balance 120,322.292 Row 4 · 2026-03-31 · Tax withholding · Disposed 4,217 · Balance 116,105.292 F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 183,639 |
Reported balance
After 2026-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-31 · Grant · Acquired 183,639 · Balance 183,639 F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-31 · Exercise / conversion · Disposed 6,555 · Balance 0 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F4: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,625 |
Reported balance
After 2026-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-31 · Exercise / conversion · Disposed 12,312 · Balance 24,625 F3: Each RSU represents a contingent right to receive one share of Organon common stock. F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
F3: Each RSU represents a contingent right to receive one share of Organon common stock.
F4: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
F5: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2023 Filed May 8, 2023 18:45 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,046 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028104 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 70,610 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · derivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,610 Underlying: Common Stock · 70,610 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 19,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · derivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,664 Underlying: Common Stock · 19,664 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,157 Underlying: Common Stock · 3,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,226 | $23.09 | $28,308.34 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,302 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023085 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 19:53 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-088175 · tm2222874-2_4seq1.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,890 Underlying: Common Stock · 12,890 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The total amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On each of August 5, 2021 and August 5, 2022, one-third of the RSUs vested with the remaining RSUs to vest in one final installment on August 5, 2023. F3 · derivative.expiration_date: On each of August 5, 2021 and August 5, 2022, one-third of the RSUs vested with the remaining RSUs to vest in one final installment on August 5, 2023. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 19:53 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,416 | $32.41 | $143,122.56 |
DisclosureSEC source: 0001104659-22-088175 · tm2222874-2_4seq1.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,950 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 19:53 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-088175 · tm2222874-2_4seq1.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 13,882 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001077183-22-000109 · wf-form4_165525370625141.xml · derivative · entry 4 Stahler Rachel A · CIK 0001679854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,882 Underlying: Common Stock · 13,882 shares Expires 2029-06-10 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 00:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000109 · wf-form4_165525370625141.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,335 Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:51 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 3,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056632 · tm2214603-8_4seq1.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3.046 Underlying: Common Stock · 3,046 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F3 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:51 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,044 | $32.44 | $33,867.36 |
DisclosureSEC source: 0001104659-22-056632 · tm2214603-8_4seq1.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,476 Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:51 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 3,046 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056632 · tm2214603-8_4seq1.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:12 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 33,068 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042365 · tm2211465-9_4seq1.xml · derivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,068 Underlying: Common Stock · 33,068 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:12 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 10,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042365 · tm2211465-9_4seq1.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,735 Underlying: Common Stock · 10,735 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:08 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033669 · doc4.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 12,890 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032180 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,785 Underlying: Common Stock · 12,890 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:46 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,416 | $28.63 | $126,430.08 |
DisclosureSEC source: 0000899243-21-032180 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,474 Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 12,890 | $28.63 | $369,040.70 |
DisclosureSEC source: 0000899243-21-032180 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:58 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 3,714 | $0.00 Strike: $40.90 | $0.00 |
DisclosureSEC source: 0001077183-21-000159 · wf-form4_162285106307216.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,714 Underlying: Common Stock · 3,714 shares Expires 2028-06-02 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 23:58 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000159 · wf-form4_162285106307216.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,779 Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 70,876 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,876 Underlying: Common Stock · 70,876 shares Expires 2031-05-03 F7 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 12,118 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,118 Underlying: Common Stock · 12,118 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F5 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 9,141 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 Underlying: Common Stock · 9,141 shares Expires 2024-05-04 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:25 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 38,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,675 Underlying: Common Stock · 38,675 shares Expires 2023-08-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 28, 2020 Filed Jun 4, 2020 22:45 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 3,448 | $0.00 Strike: $28.54 | $0.00 |
DisclosureSEC source: 0001077183-20-000141 · wf-form4_159131069488504.xml · derivative · entry 2 Stahler Rachel A · CIK 0001679854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 Underlying: Common Stock · 3,448 shares Expires 2027-05-28 Read SEC document |
| May 28, 2020 Filed Jun 4, 2020 22:45 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 2,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000141 · wf-form4_159131069488504.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,698 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.